Chernik D - Search Results

1

Illness impact and adjustment to Parkinson's disease: before and after treatment with tolcapone.

Welsh MD, Dorflinger E, Chernik D, Waters C. Welsh MD, et al. Among authors: chernik d. Mov Disord. 2000 May;15(3):497-502. doi: 10.1002/1531-8257(200005)15:3<497::AID-MDS1012>3.0.CO;2-4. Mov Disord. 2000. PMID: 10830415 Clinical Trial.

2

Utility of an objective dyskinesia rating scale for Parkinson's disease: inter- and intrarater reliability assessment.

Goetz CG, Stebbins GT, Shale HM, Lang AE, Chernik DA, Chmura TA, Ahlskog JE, Dorflinger EE. Goetz CG, et al. Among authors: chernik da. Mov Disord. 1994 Jul;9(4):390-4. doi: 10.1002/mds.870090403. Mov Disord. 1994. PMID: 7969204 Clinical Trial.

3

Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Tolcapone Fluctuator Study Group I.

Kurth MC, Adler CH, Hilaire MS, Singer C, Waters C, LeWitt P, Chernik DA, Dorflinger EE, Yoo K. Kurth MC, et al. Among authors: chernik da. Neurology. 1997 Jan;48(1):81-7. doi: 10.1212/wnl.48.1.81. Neurology. 1997. PMID: 9008498 Clinical Trial.

4

Sleep, performance, and plasma levels in chronic insomniacs during 14-day use of flurazepam and midazolam: an introduction.

Johnson LC, Chernik DA, Sateia MJ. Johnson LC, et al. Among authors: chernik da. J Clin Psychopharmacol. 1990 Aug;10(4 Suppl):5S-9S. J Clin Psychopharmacol. 1990. PMID: 2121802 Review.

5

Validity and reliability of the Neurobehavioral Assessment Scale.

Chernik DA, Tucker M, Gigli B, Yoo K, Paul K, Laine H, Siegel JL. Chernik DA, et al. J Clin Psychopharmacol. 1992 Feb;12(1):43-8. doi: 10.1097/00001573-199202000-00008. J Clin Psychopharmacol. 1992. PMID: 1552039

6

Sleep, performance, and plasma levels in chronic insomniacs during 14-day use of flurazepam and midazolam: methodology.

Chernik DA, Johnson LC, Kanitra L. Chernik DA, et al. J Clin Psychopharmacol. 1990 Aug;10(4 Suppl):10S-19S. doi: 10.1097/00004714-199008001-00003. J Clin Psychopharmacol. 1990. PMID: 2229457 Clinical Trial.

7

A multicenter study of sleep, performance, and plasma levels in chronic insomniacs during 14-day use of flurazepam and midazolam: executive summary.

Chen D, Chernik DA, Ellinwood E, Hauri P, Johnson LC, Judd LL, Kripke DF, Linnoila M, Moskowitz H, Roth T, et al. Chen D, et al. Among authors: chernik da. J Clin Psychopharmacol. 1990 Aug;10(4 Suppl):3S-4S. J Clin Psychopharmacol. 1990. PMID: 2229461 Clinical Trial. No abstract available.

8

A multicenter 14-day study of flurazepam and midazolam in chronic insomniacs: general discussion and conclusions.

Johnson LC, Chernik DA, Hauri P. Johnson LC, et al. Among authors: chernik da. J Clin Psychopharmacol. 1990 Aug;10(4 Suppl):76S-90S. J Clin Psychopharmacol. 1990. PMID: 2229466 Clinical Trial. No abstract available.

9

Sedative-hypnotics and human performance.

Johnson LC, Chernik DA. Johnson LC, et al. Among authors: chernik da. Psychopharmacology (Berl). 1982;76(2):101-13. doi: 10.1007/BF00435262. Psychopharmacology (Berl). 1982. PMID: 6805019 Clinical Trial.

10

Validity and reliability of the Observer's Assessment of Alertness/Sedation Scale: study with intravenous midazolam.

Chernik DA, Gillings D, Laine H, Hendler J, Silver JM, Davidson AB, Schwam EM, Siegel JL. Chernik DA, et al. J Clin Psychopharmacol. 1990 Aug;10(4):244-51. J Clin Psychopharmacol. 1990. PMID: 2286697 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

20 results

Search Page